Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages Fc gamma receptor IIIa (CD16a) on NK cells/macrophages to trigger ADCC and phagocytosis, plus direct caspase-independent cell death of CD20+ B cells. CD16a-expressing effector cells are not killed by the drug.